Personalized Tumor-Specific Cancer Vaccines

"Making neoantigen-based personalized cancer vaccines accessible for all pancreatic cancer patients"

NeOncoFRAx
NeOncoFRAx

Our Mission

NeOncoFRAx is a company focusing on the development and delivery of personalized neoantigen-based cancer vaccines for patients with solid tumors, with a primary focus on resected pancreatic cancer. NeOncoFRAx works closely with Erasmus MC to achieve this. Our mission is to provide a patient-accessible, safe, and effective treatment option, supported by robust scientific research and capabilities.

More Info

How It Works

Our development path—from surgery to immunotherapy—is fast, academically integrated, and uniquely patient-specific. After tumor and blood samples are collected, our in-house teams perform high-throughput sequencing to identify unique mutations in tumors. These are analyzed using advanced bioinformatics to predict neoantigens, which are then synthesized into personalized vaccine peptides. Combined with adjuvants and immune-monitoring protocols, the final vaccine is delivered to the patient to restore tumor-specific immune recognition.

More Info
NeOncoFRAx

What Patients say

"Thanks to this type of personalized cancer vaccine, I’m still here after 2.5 years. Unfortunately, such a vaccine is not available to everyone. I wish to change this by investing in this project and helping others benefit from this treatment"

- In memory of Frank Snijders, pancreatic cancer patient

What Clinicians say

"The Erasmus MC team believes that these types of advanced, personalized immunotherapies should be accessible for patients suffering from diseases for which very few treatment options are available and for a socially responsible price. The collaboration with NeOncoFRAx represents not only the scientific next step, but also an organizational commitment to society"

- Prof. Casper van Eijck & Prof. Joachim Aerts

Invest in the Future

Join us in advancing the next generation of cancer treatment. NeOncoFRAx invites forward-thinking partners to support our mission of making personalized cancer vaccines accessible to patients who need them most. Through your contribution, you help accelerate clinical research, scale innovative production, and expand the reach of personalized immunotherapy.

Learn more
NeOncoFRAx

Frequently Asked Questions

General

NeOncoFRAx is an organization focused on developing personalized, tumor-specific cancer vaccines. We work closely with Erasmus MC and other partners to make innovative immunotherapies accessible to patients.

Our initial focus is on pancreatic cancer, but our technology allows us to focus on other solid tumors in the future.

We analyze tumor and blood samples from the patient to identify unique mutations (neoantigens). Based on these, we design and produce a vaccine that specifically activates the patient's immune system against the tumor.

We strive to balance patient benefit with socially responsible pricing and have no commercial shareholders. Our mission is to make treatments broadly accessible, with socially responsible pricing.

Vaccine

The process includes: collecting tumor and blood samples, DNA/RNA sequencing, bioinformatics analysis for neoantigen discovery, peptide synthesis, vaccine formulation, and administration under medical supervision.

The entire process from sample collection to vaccine production usually takes several weeks, depending on logistics and laboratory capacity.

We share the latest news, clinical study updates, and future scientific publications through our website.

You can support us through strategic or philanthropic partnerships, joint research projects, or by contacting our management via the contact page.
Is your question not listed? Please ask your question via our contact form